BIVICTRIX
THERAPEUTICS PLC
("BiVictriX" or the "Company")
Result of Annual General
Meeting
Alderley Park, 24 July 2024 -
BiVictriX Therapeutics plc (AIM: BVX), a drug
discovery and development company applying an innovative,
proprietary approach to develop a new class of highly selective,
next generation cancer therapeutics, bispecific antibody drug
conjugates (Bi-Cygni® ADCs), which exhibit superior
potency, whilst reducing treatment-related toxicities, announces that at the Company's Annual General Meeting held
today at 3:00 pm at the Company's registered office, Mereside
Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions
were duly passed.
Further details of each of the
resolutions are set out in the Notice of Meeting, which was sent to
shareholders on 25th June 2024.
Details of proxy votes received
prior to the meeting will be made available on the Company's
website at https://bivictrix.com/investor-relations/.
The proxy results were as
follows:
|
RESOLUTION
NUMBER
|
VOTES FOR
|
VOTES
AGAINST
|
VOTES
WITHELD
|
TOTAL VOTES
|
|
1
|
10,739,609
|
0
|
0
|
10,739,609
|
|
2
|
10,739,609
|
0
|
0
|
10,739,609
|
|
2
|
10,057,109
|
682,500
|
0
|
10,739,609
|
|
4
|
10,057,109
|
682,500
|
0
|
10,739,609
|
|
5
|
10,064,609
|
675,000
|
0
|
10,739,609
|
|
6
|
10,064,609
|
675,000
|
0
|
10,739,609
|
|
ENDS
For
more information, please contact:
|
BiVictriX
Therapeutics plc
|
|
|
|
Tiffany Thorn, Chief Executive
Officer
Michael Kauffman, Non-Executive
Chairman
|
Email: info@bivictrix.com
|
|
|
|
|
|
|
SP Angel
Corporate Finance LLP (NOMAD and Broker)
|
Tel: +44 (0)
20 3470 0470
|
|
|
David Hignell, Caroline
Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
|
|
|
|
Panmure Liberum Limited (Joint Broker)
|
Tel: +44 (0)
20 7886 2500
|
|
|
Rupert Dearden/Freddy Crossley/Emma
Earl
ICR
Consilium
|
|
|
|
Mary-Jane Elliott, Namrata Taak,
Max Bennett, Emmalee Hoppe
|
Tel: +44 (0) 20 3709
5700
Email: Bivictrix@consilium-comms.com
|
|
|
|
|
|
|
|
About
BiVictriX Therapeutics plc
BiVictriX is a UK-based drug
discovery and development company which is focused on leveraging
clinical experience to develop a new class of highly selective,
next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related
toxicities.
The Company utilises a
first-in-class approach to generate a proprietary pipeline of
Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from
healthy cells.
BiVictriX has established a growing
proprietary library of cancer-specific Bi-Cygni® fingerprints,
which enable the Company to target a diverse array of different
cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug
Conjugate therapeutic design, to develop more effective and safer
therapeutics to target cancers that are expected to constitute
orphan indications and areas of high unmet medical need.
Find out more about BiVictriX online
at www.bivictrix.com
